CANOPY GROWTH CORP (OTCMKTS:TWMJF) continues to go gangbusters up the chart following news of the STZ investment. In case you have not been following, the stock has now ripped over 200% from its summertime pivot lows in the $5 area. To keep the momentum flowing, the company also just announced that it has signed a definitive licensing agreement with Farm to Farma Inc. for FTF’s innovative Trokie lozenges.
According to the release, “under this licensing agreement, Canopy Growth will have the exclusive right to manufacture and distribute FTF’s Trokie lozenges through its subsidiaries in Canada, as permitted by federal regulations, and shall have a first right of offer for all other countries where federally lawful, and excluding the United States.”
CANOPY GROWTH CORP COM NPV (OTCMKTS:TWMJF) is one of the bigger growers in N. America. The company produces and sells medical marijuana in Canada. It offers dry cannabis and oil products primarily under the Tweed and Bedrocan brands. It also sells its products through online.
According to company materials, “Tweed is the most recognized marijuana production brand in the world. It has built a large and loyal following by focusing on quality products and meaningful customer relationships. Tweed doesn’t just sell marijuana, it facilitates a conversation about a product we’ve all heard about but haven’t met intimately yet. It is approachable and friendly, yet reliable and trusted. As marijuana laws liberalize around the world, Tweed will expand its leading Canadian position around the globe.”
Also from their materials, “Developed by a Doctor of Pharmacy, Trokie lozenges have been developed to deliver a consistent and repeatable dose of cannabis to its users. Trokie features the most used polymer-based drug delivery system which allows for a zero-calorie product that avoids most common food allergies. There is no gluten, nuts, artificial flavours or colours, and the product meets vegan standards, utilizing many organic/natural ingredients.”
Find out when $TWMJF stock reaches critical levels. Subscribe to FinanceRegistrar.com Right Now by entering your Email in the box below.
As noted above, this stock has been on fire and recently added another horse to its stable of product offerings following its definitive licensing agreement with Farm to Farma Inc. for FTF’s innovative Trokie lozenges.
“We are very pleased to have entered into this license agreement for the Trokie lozenges, a cannabis product that we believe has broad medical and legal adult access market opportunities,” said Mark Zekulin, President, Canopy Growth Corporation. “We are confident value-added consumer products will drive higher margins and we will continue to look for thought leaders like Farm to Farma to expand our product offerings.”
“Combining Canopy’s vision for the future of cannabis in consumer products and the deliberate investments they are making in capacity, with our unique line of products, has positioned us to increase our global footprint with the largest and most-respected cannabis company in the world.”
“By utilizing the oral mucosa for delivery, these lozenges have been developed to minimize first pass metabolism of cannabinoids by the liver, deliver a rapid onset of action, and optimize the bioavailability of every dose,” said Dr. Kenton Crowley, the inventor of the Trokie lozenge. Additional products such as transdermal patches and capsules are being added to the suite of products available under the Trokie brand.
Traders will note 42% tacked on to share pricing for the name in the past month. The situation may be worth watching. TWMJF is a stock whose past is littered with sudden rips. Furthermore, the listing has witnessed a pop in interest, as transaction volume levels have recently pushed approaching 360% over the long run average.
At this time, carrying a capital value in the market of $1623.1M, TWMJF has a significant war chest ($116M) of cash on the books, which must be weighed relative to about $1.7M in total current liabilities. One should also note that debt has been growing over recent quarters. TWMJF is pulling in trailing 12-month revenues of $48.8M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 127.3%. We will update the story again soon as further details emerge. Sign-up for continuing coverage on shares of $TWMJF stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $TWMJF, either long or short, and we have not been compensated for this article.